NCT01788020View on ClinicalTrials.gov

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2018

Study Completion Date

April 30, 2024

Conditions
Waldenström's Macroglobulinemia
Interventions
DRUG

Dexamethasone, Rituximab, Cyclophosphamide

DRUG

Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib

Trial Locations (1)

89081

University Hospital Ulm, Ulm

All Listed Sponsors
collaborator

Centre Hospitalier de Lens (Co-Sponsor)

UNKNOWN

lead

University of Ulm

OTHER

NCT01788020 - Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | Biotech Hunter | Biotech Hunter